Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Samer Al Hadidi

CredentialsMD
MS (CRDSA)
FACP
American Board of Internal Medicine
American Board of Hematology
American Board of Medical Oncology
Michigan
Texas
Arkansas
TitleAssistant Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Medicine, College of Medicine
DivisionHematology Oncology
Address12TH FLR ACRC
4301 W. Markham
Mail Slot # 816
Little Rock AR 72205
ORCID ORCID Icon0000-0003-4297-8042 Additional info
vCardDownload vCard

    Collapse Overview 

    Collapse Affiliation 
    Collapse clinical activities
    Transplant attending

    Collapse Biography 
    Collapse Leadership and Administrative Roles
    Leader, The Foundation for the Accreditation of Cellular Therapy Accreditation Committee, University of Arkansas for Medical Sciences,Little Rock, Arkansas

    Leader, Intake meeting, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas

    Collapse education and training
    University of Jordan, Amman, JordanMD06/2011Medicine
    Michigan State University, Flint, MI06/2016Internal Medicine residency
    University of Michigan, Ann Arbor, MIMS (CRDSA)05/2017Master of Science in Clinical Research and Statistical Analysis
    Baylor College of Medicine, Houston, TX06/2021Hematology and Medical Oncology
    FDA-AACR 06/2021Drug Development oncology fellowship

    Collapse Research 
    Collapse research activities and funding
    PROTOCOL S2209     (AL HADIDI, SAMER)Jan 9, 2024 - Jan 8, 2034
    SouthWest Oncology Group
    276346 S2209, A Phase III Randomized Trial For Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail Or In A Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance
    Role: Principal Investigator
    C1071020     (AL HADIDI, SAMER)Jan 8, 2024 - Jan 7, 2034
    Pfizer, Inc.
    A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
    Role: Principal Investigator
    CAEL101     (AL HADIDI, SAMER)Jul 15, 2022 - Jul 14, 2033
    Caelum Biosciences, Inc - Pass Through: IQVIA, Inc.
    A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients
    Role: Principal Investigator
    CAEL101-301     (AL HADIDI, SAMER)Jul 15, 2022 - Jul 14, 2033
    Caelum Biosciences, Inc - Pass Through: IQVIA, Inc.
    A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients
    Role: Principal Investigator

    Collapse Outreach 

    Collapse Bibliographic 
    Collapse additional bibliographic sources
    The links below are provided by the researcher to provide access to external online bibliographies that they keep independently from the Profiles System.
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Mohan Lal B, Alzubi M, Alrawabdeh J, Shaughnessy JD, Zhan F, Siegel ER, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Al Hadidi S. Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma. Blood Adv. 2025 May 13; 9(9):2155-2158. PMID: 39938011.
      View in: PubMed
    2. Zureigat H, Adcock B, Nurse DP, Rauf A, Batah H, Ondeck M, Honnekeri B, Mercer M, Jia X, Rump M, Mirza KM, Al Hadidi S, Mustafa Ali MK. Navigating the 2022 International Consensus and World Health Organization Classifications of Hematopathology: A Call for Unified Diagnostic Language. Arch Pathol Lab Med. 2025 Apr 01; 149(4):363-367. PMID: 38952288.
      View in: PubMed
    3. Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Smith R, Panozzo S, Alapat D, Tricot G, Shaughnessy J, Zhan F, Sawyer J, Siegel ER, Barlogie B, van Rhee F, Zangari M. Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma. Blood Adv. 2025 Feb 25; 9(4):950-953. PMID: 39786380.
      View in: PubMed
    4. Mohan Lal B, van Rhee F, Al Hadidi S. Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma. Curr Oncol Rep. 2025 Mar; 27(3):258-277. PMID: 39937351.
      View in: PubMed
    5. Kakkilaya A, Trando A, Cliff ERS, Mian H, Al Hadidi S, Aziz M, Goodman AM, Jeong AR, Smith WL, Kelkar AH, Russler-Germain DA, Mehra N, Chakraborty R, Gertz MA, Mohyuddin GR. Evaluating early intervention in smoldering myeloma clinical trials: a systematic review. Oncologist. 2025 Feb 06; 30(2). PMID: 39236068.
      View in: PubMed
    6. Kattamuri L, Mohan Lal B, Vojjala N, Jain M, Sharma K, Jain S, Al Hadidi S. Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review. Rheumatol Int. 2025 Jan 04; 45(1):18. PMID: 39754644.
      View in: PubMed
    7. Mohyuddin GR, Mian H, Gayowsky A, Seow H, Chakraborty R, Pond GR, Al Hadidi S, Visram A. Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study. Blood Cancer J. 2024 Oct 16; 14(1):181. PMID: 39414772.
      View in: PubMed
    8. Patel N, Al Hadidi S, Yellapragada S. Pathophysiology and Treatments of Complications of Waldenstr?m's Macroglobulinemia. Clin Hematol Int. 2024; 6(4):11-18. PMID: 39417016.
      View in: PubMed
    9. Patel TH, Bachu R, Shrivastava T, Alrawabdeh J, Alzubi M, Hastings J, Dean H, Schinke C, Thanendrarajan S, Zangari M, Tricot G, Zhan F, Shaughnessy JD, van Rhee F, Al Hadidi S. Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. Clin Hematol Int. 2024; 6(3):54-60. PMID: 39345654.
      View in: PubMed
    10. Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Tricot G, Shaughnessy J, Zhan F, Sawyer J, Siegel ER, Zangari M, Barlogie B, van Rhee F. Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2024 Nov; 99(11):2222-2224. PMID: 39109821.
      View in: PubMed
    11. Patel T, Chen C, Al Hadidi S, Kadry Y, Sridhara R, Purcell E, Wisch L, Retzlaff J, Foti M, Pazdur R, Kluetz P, Gao J. Reflections and Roadmaps: Career Development beyond the FDA-AACR Oncology Educational Fellowship. Clin Cancer Res. 2024 Aug 01; 30(15):3144-3146. PMID: 38856702.
      View in: PubMed
    12. Naqvi S, Shrestha A, Alzubi M, Alrawabdeh J, Thanendrarajan S, Zangari M, van Rhee F, Schinke C, Al Hadidi S. Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab. EJHaem. 2024 Aug; 5(4):789-792. PMID: 39157593.
      View in: PubMed
    13. Persaud S, Al Hadidi S, Anderson TS, Gallagher G, Chimonas S, Korenstein D, Mitchell AP. Industry Payments to Physicians Endorsing Drugs and Devices on a Social Media Platform. JAMA. 2024 06 25; 331(24):2131-2134. PMID: 38814636.
      View in: PubMed
    14. Patel TH, van Rhee F, Al Hadidi S. Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2024 Nov; 24(11):762-769. PMID: 39003099.
      View in: PubMed
    15. Al Hadidi S, Heslop HE, Brenner MK, Suzuki M. Bispecific antibodies and autologous chimeric antigen receptor T?cell therapies for treatment of hematological malignancies. Mol Ther. 2024 Aug 07; 32(8):2444-2460. PMID: 38822527.
      View in: PubMed
    16. Altarawneh H, Manasrah M, Al Shanableh Y, Saed Aldien A, Manasrah MA, Khan S, Altarawneh L, Al-Kraimeen LM, Al Kasaji F, Alareeki A, Al Hadidi S. Authorship characteristics of hematology and oncology education chapters: A comprehensive analysis. J Cancer Policy. 2024 Jun; 40:100484. PMID: 38750724.
      View in: PubMed
    17. Shrestha A, Alzubi M, Alrawabdeh J, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Al Hadidi S. B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma. EJHaem. 2024 Jun; 5(3):554-559. PMID: 38895072.
      View in: PubMed
    18. Elemian S, Al Hadidi S. Targeting GPRC5D in multiple myeloma. Expert Rev Anticancer Ther. 2024 May; 24(5):229-238. PMID: 38607646.
      View in: PubMed
    19. Al Hadidi S. Clinical trials of T-cell re-directing therapy in plasma cell precursor conditions. Eur J Cancer. 2024 May; 203:114045. PMID: 38604006.
      View in: PubMed
    20. Guo W, Strouse C, Mery D, Siegel ER, Munshi MN, Ashby TC, Cheng Y, Sun F, Wanchai V, Zhang Z, Bailey C, Alapat DV, Peng H, Al Hadidi S, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation. Cancers (Basel). 2024 Mar 11; 16(6). PMID: 38539451.
      View in: PubMed
    21. Rafae A, van Rhee F, Al Hadidi S. Perspectives on the Treatment of Multiple Myeloma. Oncologist. 2024 Mar 04; 29(3):200-212. PMID: 37995307.
      View in: PubMed
    22. Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2024 03 01; 109(3):906-914. PMID: 37646658.
      View in: PubMed
    23. Al Hadidi S, Ababneh OE, Schinke CD, Thanendrarajan S, Bailey C, Smith R, Panozzo S, Alapat D, Cottler-Fox M, Tricot G, Shaughnessy JD, Zhan F, Sawyer J, Barlogie B, Zangari M, van Rhee F. Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up. Blood Adv. 2024 02 13; 8(3):703-707. PMID: 38052037.
      View in: PubMed
    24. Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H, Gai D, Siegel E, Bailey C, Ashby C, Al Hadidi S, Schinke C, Thanendrarajan S, Ma Y, Yi Q, Orlowski RZ, Zangari M, van Rhee F, Janz S, Bishop G, Tricot G, Shaughnessy JD, Zhan F. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024 Jan 19; 15(1):615. PMID: 38242888.
      View in: PubMed
    25. Sun F, Cheng Y, Chen JR, Wanchai V, Mery DE, Xu H, Gai D, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. J Clin Invest. 2024 Jan 02; 134(1). PMID: 37883186.
      View in: PubMed
    26. Abusamak AA, Abusamak M, Al-Abbadi M, Rayyan A, Oran O, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Cliff ERS, Al Hadidi S. Use of subjective minimizing language at hematology and oncology conferences: A systematic review. J Cancer Policy. 2024 Mar; 39:100461. PMID: 38061494.
      View in: PubMed
    27. Najjar M, McCarron J, Cliff ERS, Berger K, Steensma DP, Al Hadidi S, Chakraborty R, Goodman A, Anto E, Greene T, Sborov D, Mohyuddin GR. Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma. JAMA Netw Open. 2023 11 01; 6(11):e2342195. PMID: 37948080.
      View in: PubMed
    28. Alrawabdeh J, Alzu'bi M, Alzyoud M, Odeh N, Hamadneh Y, Mian H, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Russler-Germain DA, Mehra N, Baggio D, Cliff ERS, Al Hadidi S. Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review. JNCI Cancer Spectr. 2023 10 31; 7(6). PMID: 38006333.
      View in: PubMed
    29. Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Guo W, Cao H, Zhu Y, Ashby C, Bauer MA, Nookaew I, Siegel ER, Ying J, Chen JR, Gai D, Peng B, Xu H, Bailey C, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, Chesi M, Bergsagel PL, van Rhee F, Janz S, Tricot G, Shaughnessy JD, Zhan F. High NEK2 expression in myeloid progenitors suppresses T?cell immunity in multiple myeloma. Cell Rep Med. 2023 10 17; 4(10):101214. PMID: 37794587.
      View in: PubMed
    30. Hussain M, Yellapragada S, Al Hadidi S. Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article. Blood Lymphat Cancer. 2023; 13:33-57. PMID: 37731771.
      View in: PubMed
    31. Wu C, Dongarwar D, Al Hadidi S. Racial Disparities in Plasma Cell Leukemia Outcomes Among Hospitalized Patients in the United States. Clin Hematol Int. 2023; 5(4):1-9. PMID: 37752989.
      View in: PubMed
    32. Chakraborty R, Al Hadidi S, Cliff ERS, Mohyuddin GR. Is aggressive treatment of smoldering myeloma the path to curing myeloma? Blood Adv. 2023 08 08; 7(15):3932-3935. PMID: 37196639.
      View in: PubMed
    33. Fahmawi S, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, Zhan F, van Rhee F, Al Hadidi S. Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines. J Cancer Policy. 2023 09; 37:100433. PMID: 37468042.
      View in: PubMed
    34. Mazahreh F, Mazahreh L, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, Zhan F, van Rhee F, Al Hadidi S. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023 Jul 11; 7(13):3069-3074. PMID: 36857755.
      View in: PubMed
    35. Ali MO, Abdullah HM, Obeidat K, Chakraborty R, Al Hadidi S. Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review. EJHaem. 2023 Aug; 4(3):719-722. PMID: 37601879.
      View in: PubMed
    36. Sun F, Cheng Y, Ying J, Mery D, Al Hadidi S, Wanchai V, Siegel ER, Xu H, Gai D, Ashby TC, Bailey C, Chen JR, Schinke C, Thanendrarajan S, Zangari M, Janz S, Barlogie B, Van Rhee F, Tricot G, Shaughnessy JD, Zhan F. A gene signature can predict risk of MGUS progressing to multiple myeloma. J Hematol Oncol. 2023 06 29; 16(1):70. PMID: 37386588.
      View in: PubMed
    37. Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse C, Badawy SM, Al Hadidi S, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh M, Munshi PN, Nishihori T, Anderson LD, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023 06 27; 7(12):2746-2757. PMID: 36827681.
      View in: PubMed
    38. Shrivastava T, Van Rhee F, Al Hadidi S. Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives. Onco Targets Ther. 2023; 16:441-464. PMID: 37359353.
      View in: PubMed
    39. Mohan M, Gong Z, Ashby TC, Al Hadidi S, Thanendrarajan S, Schinke C, Alapat D, Shaughnessy JD, Zhan F, van Rhee F, Sawyer JR, Tian E, Zangari M. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. Cancer. 2023 08 15; 129(16):2491-2498. PMID: 37282609.
      View in: PubMed
    40. Chakraborty R, Al Hadidi S. Intent Matters: Real-World Applicability of Idecabtagene Vicleucel Usage in the United States. J Clin Oncol. 2023 07 10; 41(20):3657-3658. PMID: 37235838.
      View in: PubMed
    41. Abu Za'nouneh FJ, Ababneh O, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, Zhan F, van Rhee F, Al Hadidi S. Variability of definition of high-risk multiple myeloma across phase III clinical trials. EJHaem. 2023 May; 4(2):454-458. PMID: 37206288.
      View in: PubMed
    42. Mazahreh F, Al-Hader AA, Al Hadidi S. Visa Constraints and Career Choices for Oncologists. J Natl Compr Canc Netw. 2023 03; 21(3):332-334. PMID: 36898360.
      View in: PubMed
    43. Al Hadidi S, Dongarwar D, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, van Rhee F. Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma. Clin Hematol Int. 2023 Jun; 5(2-3):57-60. PMID: 36737587.
      View in: PubMed
    44. Al Hadidi S, Abu Zaid MI, Mustafa Ali M. Institutional disparities in the distribution of the American Society of Clinical Oncology grants. J Cancer Policy. 2023 03; 35:100404. PMID: 36649905.
      View in: PubMed
    45. Al Hadidi S, van Rhee F. Overall Survival Analysis of the Use of Elotuzumab in ELOQUENT-3 Trial. J Clin Oncol. 2023 03 20; 41(9):1788. PMID: 36626704.
      View in: PubMed
    46. Al Hadidi S, Abuali I. The Inflation in Oncology Publications and Journals: A Vicious Cycle That Needs Immediate Attention. Cancer Invest. 2023 Jan 05; 1-3. PMID: 36592137.
      View in: PubMed
    47. Anampa-Guzm?n A, Alam ST, Abuali I, Al Hadidi S. Health Disparities Experienced by Hispanic Americans with Multiple Myeloma: A Systematic Review. Clin Hematol Int. 2023 Mar; 5(1):29-37. PMID: 36586086.
      View in: PubMed
    48. Al Hadidi S, Cliff ERS. CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma. Eur J Cancer. 2023 03; 182:1-2. PMID: 36680878.
      View in: PubMed
    49. Syaj S, Al-Kraimeen L, Akhdar M, Abushukair H, Mohty R, Al Hadidi S. Gender and early-career faculty disparities in hematology and?oncology board review lecture series. Blood Adv. 2022 12 27; 6(24):6213-6218. PMID: 35894637.
      View in: PubMed
    50. Al Hadidi S, Szabo A, Esselmann J, Hammons L, Hussain M, Ogunsesan Y, Thalambedu N, Khan F, Sethi J, Janardan A, Radhakrishnan SV, Thanendrarajan S, Schinke C, Dhakal B, Janz S, Chhabra S, D'Souza A, Zangari M, van Rhee F, Mohan M. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone Marrow Transplant. 2023 04; 58(4):443-445. PMID: 36550200.
      View in: PubMed
    51. Sawalha L, Kelkar AH, Mohyuddin GR, Goodman AM, Gagelmann N, Al Hadidi S. Analysis of repeated roles in editorial boards at oncology focused journals. J Cancer Policy. 2023 03; 35:100380. PMID: 36538988.
      View in: PubMed
    52. Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin GR. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol. 2023 03; 200(5):587-594. PMID: 36495317.
      View in: PubMed
    53. Schinke C, Poos AM, Bauer M, John L, Johnson S, Deshpande S, Carrillo L, Alapat D, Rasche L, Thanendrarajan S, Zangari M, Al Hadidi S, van Rhee F, Davies F, Raab MS, Morgan G, Weinhold N. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood Adv. 2022 11 22; 6(22):5873-5883. PMID: 35977111.
      View in: PubMed
    54. Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Price M, Shirey M, Warner D, Thanendrarajan S, Janz S, Radhakrishnan SV, Al Hadidi S, Szabo A, D'Souza A, Zangari M, van Rhee F, Chhabra S, Schinke C. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. Am J Hematol. 2022 12; 97(12):E451-E453. PMID: 36097868.
      View in: PubMed
    55. Hussain M, Khan F, Al Hadidi S. The use of bone-modifying agents in multiple myeloma. Blood Rev. 2023 01; 57:100999. PMID: 36050125.
      View in: PubMed
    56. Alqazaqi R, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy J, Zhan F, Tricot G, van Rhee F, Al Hadidi S. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA Netw Open. 2022 08 01; 5(8):e2228877. PMID: 36018590.
      View in: PubMed
    57. Fatoki RA, Koehn K, Kelkar A, Al Hadidi S, Mehra N, Mian H, Landgren O, Kazandjian D, Hoffman J, Sborov DW, Mohyuddin GR. Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. JCO Glob Oncol. 2022 08; 8:e2200119. PMID: 35960904.
      View in: PubMed
    58. Al Hadidi S, Dongarwar D, Salihu H, Schinke C, Thanendrarajan S, Zangari M, van Rhee F. Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States. Clin Hematol Int. 2022 Sep; 4(3):117-120. PMID: 36131130.
      View in: PubMed
    59. Thalambedu N, Al Hadidi S. Thromboprophylaxis in multiple myeloma. Leuk Lymphoma. 2022 12; 63(12):2807-2815. PMID: 35759648.
      View in: PubMed
    60. Ali MO, Al Hadidi S. High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma. Transplant Cell Ther. 2022 09; 28(9):572-580. PMID: 35750284.
      View in: PubMed
    61. Dweik A, Dweik H, Mian H, Mohan M, Schinke C, Al Hadidi S. Gender disparities in multiple myeloma publications. EJHaem. 2022 Aug; 3(3):966-969. PMID: 36051049.
      View in: PubMed
    62. Al Hadidi S, Zangari M, van Rhee F. Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions. JAMA Oncol. 2022 06 01; 8(6):823-824. PMID: 35482363.
      View in: PubMed
    63. Ababneh O, Abushukair H, Qarqash A, Syaj S, Al Hadidi S. The Use of Bruton Tyrosine Kinase Inhibitors in Waldenstr?m's Macroglobulinemia. Clin Hematol Int. 2022 Jun; 4(1-2):21-29. PMID: 35950210.
      View in: PubMed
    64. Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. Am J Hematol. 2022 07; 97(7):E276-E280. PMID: 35472167.
      View in: PubMed
    65. Abushukair H, Syaj S, Ababneh O, Qarqash A, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Al Hadidi S. First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenstr?m's Macroglobulinemia: A systematic review and meta-analysis. Am J Hematol. 2022 07; 97(7):942-950. PMID: 35358350.
      View in: PubMed
    66. Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA Netw Open. 2022 04 01; 5(4):e228161. PMID: 35442451.
      View in: PubMed
    67. Hadidi SA. Melflufen in multiple myeloma: the conclusion matters. Lancet Haematol. 2022 04; 9(4):e244. PMID: 35358437.
      View in: PubMed
    68. Mohan M, Gundarlapalli S, Szabo A, Yarlagadda N, Kakadia S, Konda M, Jillella A, Fnu A, Ogunsesan Y, Yarlagadda L, Thalambedu N, Munawar H, Graziutti M, Al Hadidi S, Alapat D, Thanendrarajan S, Zangari M, van Rhee F, Schinke C. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. Am J Hematol. 2022 06 01; 97(6):E195-E198. PMID: 35285981.
      View in: PubMed
    69. Larsen K, Spencer H, Mohan M, Bailey C, Hill K, Kottarathara M, Parikh R, Hoque S, Erra A, Mitma AA, Mathur P, Yarlagadda L, Gundarlapalli S, Ogunsesan Y, Hussain M, Thalambedu N, Sehti J, Al Hadidi S, Thanendrarajan S, Graziutti M, Zangari M, Barlogie B, van Rhee F, Tricot G, Schinke C. Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. J Clin Med. 2022 Mar 16; 11(6). PMID: 35329966.
      View in: PubMed
    70. Al Hadidi S. The Use of Modified Surrogate End Points in Cancer Clinical Trials. Cancer Invest. 2022 01; 40(1):14-16. PMID: 34775893.
      View in: PubMed
    71. Al Hadidi S, Kamble RT, Carrum G, Heslop HE, Ramos CA. Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies. Blood Adv. 2021 11 23; 5(22):4630-4633. PMID: 34461636.
      View in: PubMed
    72. Al Hadidi S, Yellapragada S. Treatment Options for Relapsed and Refractory Multiple Myeloma: A Luxury or a Challenge? JAMA Oncol. 2021 10 01; 7(10):1449-1450. PMID: 34383000.
      View in: PubMed
    73. Nanah A, Al Hadidi S. Bing-Neel Syndrome: Update on the Diagnosis and Treatment. Clin Lymphoma Myeloma Leuk. 2022 03; 22(3):e213-e219. PMID: 34674984.
      View in: PubMed
    74. Al Hadidi S, Dongarwar D, Salihu HM, Kamble RT, Lulla P, Hill LC, Carrum G, Ramos CA, Heslop HE, Usmani SZ. Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study. Leuk Lymphoma. 2021 12; 62(13):3256-3263. PMID: 34278937.
      View in: PubMed
    75. Awidi M, Al Hadidi S. Participation of Black Americans in Cancer Clinical Trials: Current Challenges and Proposed Solutions. JCO Oncol Pract. 2021 05; 17(5):265-271. PMID: 33974816.
      View in: PubMed
    76. Caro J, Al Hadidi S, Usmani S, Yee AJ, Raje N, Davies FE. How to Treat High-Risk Myeloma at Diagnosis and Relapse. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:291-309. PMID: 34010042.
      View in: PubMed
    77. Al Hadidi S, Ramos CA. Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies. Leuk Lymphoma. 2021 06; 62(6):1522-1524. PMID: 33491524.
      View in: PubMed
    78. Al-Hadidi SA, Lee HJ. Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma. JCO Oncol Pract. 2021 02; 17(2):64-71. PMID: 33434064.
      View in: PubMed
    79. Al Hadidi SA, Lee HJ. Pembrolizumab for the treatment of Hodgkin Lymphoma. Expert Opin Biol Ther. 2020 11; 20(11):1275-1282. PMID: 33006479.
      View in: PubMed
    80. Al-Hadidi SA, Chuang HH, Miranda RN, Lee HJ. Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2021 02; 21(2):e105-e111. PMID: 33160934.
      View in: PubMed
    81. Al Hadidi S, Mims M, Miller-Chism CN, Kamble R. Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs. Ann Intern Med. 2020 08 18; 173(4):320-322. PMID: 32568574.
      View in: PubMed
    82. Al Hadidi S, Miller-Chism CN, Kamble R, Mims M. Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):e579-e589. PMID: 32409106.
      View in: PubMed
    83. Al Hadidi S, Udden M. Autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia. Clin Case Rep. 2020 Jun; 8(6):1112-1113. PMID: 32577278.
      View in: PubMed
    84. Kyi HH, Zayed Y, Al Hadidi S. Ibrutinib-induced cardiomyopathy. J Community Hosp Intern Med Perspect. 2019; 9(1):50-52. PMID: 30788077.
      View in: PubMed
    85. Kheiri B, Osman M, Al Hadidi S. From a burn scar to malignancy! Marjolin's ulcer, a disease of wound neglect. Oxf Med Case Reports. 2018 Aug; 2018(8):omy044. PMID: 30151214.
      View in: PubMed
    86. Badami S, Upadhaya S, Velagapudi RK, Mikkilineni P, Kunwor R, Al Hadidi S, Bachuwa G. Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors. J Oncol. 2018; 2018:6279871. PMID: 30112001.
      View in: PubMed
    87. Daher H, Towfiq B, Al Hadidi S. Gradually Worsening Pruritic Plaques. JAMA Oncol. 2018 Apr 01; 4(4):573-574. PMID: 29145542.
      View in: PubMed
    88. Al Hadidi S, Aburahma A, Badami S, Upadhaya S. PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials. Oncol Res Treat. 2018; 41(4):226-235. PMID: 29562224.
      View in: PubMed
    89. Jarrah J, Samji V, Meshesha M, Kothuru C, Al Hadidi S. Methicillin-resistant Staphylococcus aureus prostatic abscess after traumatic rectal injury. Oxf Med Case Reports. 2018 Mar; 2018(3):omx111. PMID: 29593878.
      View in: PubMed
    90. Al Hadidi S. Delayed Adjuvant Chemotherapy and Survival After Lung Cancer Surgery. JAMA Oncol. 2018 02 01; 4(2):262. PMID: 28975199.
      View in: PubMed
    91. Al Hadidi S. Timing of Pregnancy and Survival in Women With Breast Cancer. JAMA Oncol. 2018 01 01; 4(1):131. PMID: 28880981.
      View in: PubMed
    92. Daher H, Al Hadidi S. Dysphagia lusoria presenting as epigastric pain. BMJ Case Rep. 2017 Dec 05; 2017. PMID: 29212867.
      View in: PubMed
    93. Al Hadidi S, Upadhaya S, Shastri R, Alamarat Z. Use of dictation as a tool to decrease documentation errors in electronic health records. J Community Hosp Intern Med Perspect. 2017; 7(5):282-286. PMID: 29147468.
      View in: PubMed
    94. Elounais F, Aburahma A, Alkotob ML, Al Hadidi S. Ventricular tachycardia after initiation of fingolimod. BMJ Case Rep. 2017 Sep 27; 2017. PMID: 28954755.
      View in: PubMed
    95. Badami S, Kyi HH, Upadhaya S, Al Hadidi S. Pancreatic Adenocarcinoma Masquerading as Idiopathic Chronic Pancreatitis with Delayed Diagnosis. Case Rep Oncol. 2017 Sep-Dec; 10(3):819-823. PMID: 29070996.
      View in: PubMed
    96. Al Hadidi S, Wu K, Aburahma A, Alamarat Z. Family with clots: antithrombin deficiency. BMJ Case Rep. 2017 Aug 11; 2017. PMID: 28801334.
      View in: PubMed
    97. Chughtai K, Gupta R, Upadhaya S, Al Hadidi S. Topical 5-Fluorouracil associated skin reaction. Oxf Med Case Reports. 2017 Aug; 2017(8):omx043. PMID: 28845237.
      View in: PubMed
    98. Alamarat Z, Onwuzurike N, Azher Q, Al Hadidi S. Huge teratoma in a teenager. Oxf Med Case Reports. 2017 Aug; 2017(8):omx040. PMID: 28852533.
      View in: PubMed
    99. Hadidi SA, Shastri R. Vanishing Lung Syndrome. J Am Osteopath Assoc. 2017 08 01; 117(8):541. PMID: 28759097.
      View in: PubMed
    100. Kyi HH, Aljariri Alhesan N, Upadhaya S, Al Hadidi S. Seizure Associated Takotsubo Syndrome: A Rare Combination. Case Rep Cardiol. 2017; 2017:8458054. PMID: 28811941.
      View in: PubMed
    101. Abdalla A, Bachuwa G, Al Hadidi S. A case of hypercalcemia with double pathology. J Community Hosp Intern Med Perspect. 2017 Jul; 7(3):178-181. PMID: 28808512.
      View in: PubMed
    102. Upadhaya S, Baig M, Towfiq B, Al Hadidi S. Nodular pulmonary amyloidosis with primary pulmonary MALT lymphoma masquerading as metastatic lung disease. J Community Hosp Intern Med Perspect. 2017 Jul; 7(3):185-189. PMID: 28808514.
      View in: PubMed
    103. Osman M, Al Salihi M, Abu Sitta E, Al Hadidi S. A rare case of Epstein-Barr virus mucocutaneous ulcer of the colon. BMJ Case Rep. 2017 Jul 06; 2017. PMID: 28687701.
      View in: PubMed
    104. Al Hadidi S, Tareen K. Air in the portal vein: where computed tomography saved a patient's life. Oxf Med Case Reports. 2017 Apr; 2017(4):omx015. PMID: 28473923.
      View in: PubMed
    105. Al Hadidi S, Katato K, Bachuwa G. Immunoglobulin D Multiple Myeloma Presenting as Spontaneous Fracture. Case Rep Oncol. 2017 Jan-Apr; 10(1):272-275. PMID: 28512409.
      View in: PubMed
    106. Al Hadidi S. Aspirin and Cancer Risk. JAMA Oncol. 2016 10 01; 2(10):1371-1372. PMID: 27533744.
      View in: PubMed
    107. Al Hadidi S, Haddad RA, Abed F, Bachuwa G. Penile gangrene as a sign of uncontrolled diabetes mellitus. BMJ Case Rep. 2016 Feb 05; 2016. PMID: 26851255.
      View in: PubMed
    108. Al Hadidi S, Shaik Mohammed T, Bachuwa G. Unusual presentation of uterine leiomyoma. BMJ Case Rep. 2015 Apr 09; 2015. PMID: 25858937.
      View in: PubMed
    109. Al Hadidi S, Towfiq B, Bachuwa G. Dystextia as a presentation of stroke. BMJ Case Rep. 2014 Nov 20; 2014. PMID: 25414224.
      View in: PubMed
    Al Hadidi's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (183) concept(s)
    _
    Co-Authors Expand Description
    See all (24) people
    _
    Similar People Expand Description
    See all (30) people
    _
    Same Department Expand Description
    Search Department